Could a new drug help tiny babies feed faster?

NCT ID NCT05670951

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called ELGN-2112 in preterm infants born between 26 and 32 weeks who have trouble absorbing food. The goal is to see if the drug helps them reach full feeding sooner compared to a placebo. About 360 babies will take part in this Phase 3 trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

ELGN-2112 (human insulin made from recombinant DNA)

What this could lead to

If it works, this could help preterm babies with gut problems reach full feeding sooner, reducing hospital stays and complications.

What could go wrong

This is still a controlled trial, and the treatment may not work better than placebo. Risks in preterm infants are always high, and the drug's safety is still being studied.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTESTINAL MALABSORPTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malabsorption syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.

Contacts and locations

Locations

  • Laniado Hospital

    RECRUITING

    Netanya, 4244916, Israel

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••